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Background: Genetic BRCA2 insufficiency is associated with breast cancer development; however, in sporadic
breast cancer cases, high BRCA2 expression is paradoxically correlated with poor prognosis. Because DSS1, a
mammalian component of the transcription/RNA export complex, is known to stabilize BRCA2, we investigated
how the expression of DSS1 is associated with clinical parameters in breast cancers.
Methods: DSS1 mRNA and p53 protein were examined by RT-PCR and immunohistochemical staining of breast
cancer specimens to classify DSS1high and DSS1low or p53high and p53low groups. Patient survival was compared
using Kaplan-Meier method. DSS1high or DSS1low breast cancer cells were prepared by retroviral cDNA transfection
or DSS1 siRNA on proliferation, cell cycle progression, and survival by flow cytometric analyses with or without
anti-cancer drugs.
Results: In comparison to patients with low levels of DSS1, high-DSS1 patients showed a poorer prognosis, with
respect to relapse-free survival period. The effect of DSS1 was examined in breast cancer cells in vitro. DSS1
high-expression reduces the susceptibility of MCF7 cells to DNA-damaging drugs, as observed in cell cycle and
apoptosis analyses. DSS1 knockdown, however, increased the susceptibility to the DNA-damaging drugs
camptothecin and etoposide and caused early apoptosis in p53 wild type MCF7 and p53-insufficient MDA-MB-231
cells. DSS1 knockdown suppresses the proliferation of drug-resistant MDA-MB-231 breast cancer cells, particularly
effectively in combination with DNA-damaging agents.
Conclusion: Breast cancers with high DSS1 expression have worse prognosis and shorter relapse-free survival
times. DSS1 is necessary to rescue cells from DNA damage, but high DSS1 expression increases drug resistance.
We suggest that DSS1 expression could be a useful marker for drug resistance in breast cancers, and DSS1
knockdown can induce tumor apoptosis when used in combination with DNA-damaging drugs.
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Breast cancer development is associated with various
molecular abnormalities in genes involved in DNA repair,
cell cycle control, signal transduction, and tumor suppres-
sor function; these are the predisposing hereditary causes
in approximately 5-10% of breast cancers [1]. Hereditary
breast cancers exhibit germline mutations of BRCA1 and* Correspondence: nobusaka@kumamoto-u.ac.jp
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reproduction in any medium, provided the orBRCA2 at certain incidences. Most breast cancer cases
with germline BRCA2 mutations have loss of heterozygos-
ity at the BRCA2 locus, resulting in the loss of the BRCA2
allele [2,3]. BRCA2 deficiency is associated with various
abnormalities in the response to DNA cross-linking agents,
such as defects in homologous recombination (HR), forma-
tion of RAD51 foci, DNA replication, and checkpoint
regulation [4-9].
In contrast, in the majority (90%) of sporadic breast
cancers, BRCA2 is not mutated [10]. Rather, the expres-
sion of BRCA2 is increased in tumors, as shown in reverseLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and immunohistochemical analyses [11]. BRCA2 is signifi-
cantly over-expressed in sporadic breast, ovarian, pancre-
atic, and prostatic cancers [12]. BRCA2 over-expression,
but not decreased expression, was correlated with his-
topathological grade III; this over-expression, which is
attributable to nuclear polymorphism, was also correlated
with the mitotic index, implicating a close association
between BRCA2 over-expression and the proliferation rate
of breast cancer cells [11,13]. Furthermore, a three-gene
expression signature (BRCA2, DNMTB3, and CCNEI) was
found to be an independent prognostic marker in breast
cancer [14]. A high BRCA2 level is associated with poor
outcome and correlated with high proliferation rate. In a
hierarchical clustering analysis of 47 candidate genes,
BRCA2 was found to be the leading gene in a cluster of
proliferation-associated genes. The finding was supported
by an in vitro study in which BRCA2 over-expression
suppressed HR and reduced RAD51 foci formation, along
with inactivation of p53, which suggests that moderate
levels of BRCA2 play a role in the stimulation of HR for
appropriate DNA repair [15].
The expression level of BRCA2 is presumably regula-
ted through various mechanisms including transcription,
subcellular localization, binding to partners, and protein
modification and stabilization. A stabilization factor of
BRCA2, deleted in split hand/split foot 1 (DSS1), was
originally identified as a BRCA2-associated protein, and
its depletion was shown to induce BRCA2 destabilization
[16]. DSS1 is a candidate gene for an inherited limb devel-
opment disease and is located on chromosome 7q21.3–
q22.1. DSS1 is a principal component of the mammalian
mRNA transcription/exportation 2 (TREX2) complex that
includes GANP, PCID2, and DSS1 and interacts with
various components of RNA metabolism including RNA
polymerase II, RNA splicing factors, and helicases [17].
Saccharomyces deficient in the components of the TREX2
complex displayed abnormalities in cell proliferation and
cell cycle control, but abnormal expression of individual
components of TREX2 results in different phenotypes in
mammalian cells. For example, mammalian GANP insuffi-
ciency causes DNA injuries during proliferation and is
associated with tumor development in human glioblast-
oma [18]. Loss of PCID, another TREX2 component,
causes a severe defect in Mad2 expression with a marked
reduction in Mad2 mRNA export, which causes severe
hyperploidy and apoptotic cell death [19]. However,
increased expression of TREX2 components, in contrast
to reduced expression, has rarely been shown to be associ-
ated with tumor development.
Given that the BRCA2-expression is correlated with
poor prognosis in clinical cases [11,13], we investigated
the outcome of abnormal DSS1 expression in human
breast cancer cases. DSS1 is certainly expressed at highlevels in a group of breast cancer cases with poor prog-
nosis. The imbalance of DSS1 over-expression associated
with BRCA2 expression could affect breast cancer devel-
opment. Here, we demonstrate that increased DSS1 ex-
pression is correlated with chemo-resistance in sporadic
breast cancers, which might be responsible for the worse
prognosis of patients with high DSS1 levels, particularly
with respect to relapse-free survival (RFS).
Methods
Patients and breast cancer tissues
Breast tumor specimens from 289 female patients with in-
vasive breast carcinoma, who were treated at Kumamoto
University Hospital between 2001 and 2009, were inclu-
ded in this study. Among these patients, p53 immuno-
histochemical data were available for 227 (78.5%) patients.
The patients were from a consecutive series; those with
other malignancies or bilateral breast cancer were exclu-
ded. Samples were snap frozen in liquid nitrogen at the
time of the pretherapeutic biopsy or surgical treatment
and stored at −80°C until simultaneous total RNA extrac-
tion. The median age of the patients was 59 years (range,
21–93 years). Adjuvant treatment and neoadjuvant treat-
ment were decided by risk evaluation according to tumor
biology [estrogen receptor alpha (ERα), progesterone re-
ceptor (PgR), and HER2 but not Ki-67 status] and clinical
staging, including sentinel lymph node biopsy, in accord-
ance with the recommendations of the St. Gallen inter-
national expert consensus on the primary therapy of early
breast cancer. In detail, neoadjuvant treatments were
administered to 62 patients, 46 of whom received chemo-
therapy and 16 of whom received hormonal therapy. The
breast-conserving rate was 68.2%, and most of these were
treated with radiotherapy. Axillary lymph node dissection
was carried out in 45.2% of cases; the others were spared
dissection due to negative lymph node status by sentinel
node exploration. A total of 208 patients were treated with
hormone therapy, 106 patients were given chemotherapy,
and 19 patients were treated with trastuzumab. The ethics
committee of Graduate School of Medical Sciences,
Kumamoto University approved the study protocol. In-
formed consent was obtained from all patients. Patients
received follow-up studies every 3 months. The median
follow-up period was 66 months (range 15–144 months).
RNA extraction, primers, and qRT-PCR
Total RNA was isolated from tissue specimens using the
Allprep DNA/RNA Mini Kit (Qiagen, Germantown,
MD). Total RNA (0.5 μg) was reverse transcribed to
cDNA using PrimeScript RT reagent Kit (Takara Bio Inc.,
Otsu, Japan), according to the manufacturer’s protocol.
Each PCR was performed using 2 μl of cDNA and
0.2 μmol/l of each probe in a LightCycler System with
SYBR Premix Dimer Eraser (Takara Bio Inc.). PCR primer
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GAGGAAGACGACGAGT-3′ and reverse 5′-GGATGCT
ATGAAGTCTCCAT-3′; for β-actin, forward 5′-TGGCA
CCCAGCACAATGAA-3′ and reverse 5′-CTAAGTCA
TAGTCCGCCTAGAAGCA-3′. Each reaction (20 μl
samples) was performed under the following conditions:
initialization for 10 sec at 95°C, and then 45 cycles of
amplification, with 5 sec at 95°C for denaturation and
20 sec at 60°C for annealing and elongation. The ex-
pression level of DSS1 mRNA is given as relative copy
numbers normalized to those of β-actin mRNA. In some
experiments, qRT-PCR was performed using a LightCycler
(Roche Diagnostics, Indianapolis, IN). Specific oligonuc-
leotide primers and probes for DSS1 and gapdh were
purchased (Nihon Gene Research Laboratories, Sendai,
Japan). The specific primers for DSS1 were the same
as above. Their sequences were as follows: dss1 donor
probe, 5′-CCCAATTATCCTCCCAGACATGTGCATC
TT-3′; dss1 acceptor probe, 5′-ATCTTCATCTAAGC
CAGCCCAGTCTTCGG-3′; gapdh-F, 5-CAGCCTCAA
GATCATCAGC-3′; gapdh-R, 5′-GGCCATCCACAGT
CTTCT-3′; gapdh donor probe, 5′-GGTCATCCAT
GACAACTTTGGTATCGTGGAA-3′; gapdh acceptor
probe, 5′-GACTCATGACCACAGTCCATGCCATCA
CTG-3′. The level of DSS1 mRNA expression was
determined relative to gapdh.
Immunohistochemistry and scoring system
Histological sections (4 μm) were deparaffinized and
incubated for 10 min in methanol containing 0.3%
hydrogen peroxide. Mouse monoclonal antibodies
(mAbs) against ERα (SP1, Ventana Japan, Tokyo, Japan),
PgR (1E2, Ventana Japan) and Ki67 (MIB1, Dako Japan,
Tokyo, Japan), a polyclonal Ab against HER2 (Dako
Japan), and a mouse mAb against p53 (DO7, Dako
Japan) were used; staining was carried out in the NexES
IHC Immunostainer (Ventana Medical Systems, Tucson,
AZ), in accordance with the manufacturer's instructions.
ERα and PgR status were evaluated based on the per-
centage of positively stained nuclei, and the status of a
nucleus was considered positive when ≥1% of the
nucleus was stained. HER2 was evaluated using the
HercepTest method (Dako Japan), with membranous
staining scored on a scale of 0 to 3+. Tumors with
scores of ≥3 or with a ≥2.2-fold increase in HER2 gene
amplification as determined by fluorescence in situ
hybridization were considered to be positive for HER2
over-expression. Ki67 was scored as the percentage of
nuclear-stained cells out of all cancer cells along the in-
vasive front of the tumor in × 400 high-power fields; this
gave the Ki67 labeling index. p53 was evaluated based
on the percentage of positively stained nuclei, and the
status of a nucleus was considered positive when ≥20%
of the nucleus was stained.Cell lines and small interfering RNA (siRNA) treatment
The human breast cancer cell lines MCF7 and MDA-
MB-231 were obtained from the American Type Culture
Collection and maintained in RPMI-1640 (Life Tech-
nologies, Carlsbad, CA) supplemented with 10% heat-
inactivated fetal calf serum (MP Biomedicals, Santa Ana,
CA), 2 mM L-glutamine (Lonza, Allendale, NJ), and 5 ×
10-5 M 2-mercaptoethanol (Wako Pure Chemicals In-
dustries, Osaka, Japan) with 5% CO2 at 37°C. siRNA
treatment was performed when the cells reached 50%
confluence; cells were transfected with 10 nM of con-
trol (siCtrl) or DSS1 (siDSS1; Life Technologies)
siRNA using Lipofectamine RNAiMAX (Life Tech-





UUCAGAUCUGGUGCUUA-3′. The results with siDS
S1-(a) are shown in the figures as representatives.
Establishment of DSS1 over-expressing cells
A retroviral vector, designated pFB-DSS1-IRES-GFP, was
transfected into PLAT-GP (Cellbiolabs, San Diego, CA)
retrovirus packaging cells using FuGENE HD (Roche
Diagnostics). MCF7 and MDA-MB-231 cells were infected
with the retroviruses using polybrene (8 μg/ml; Sigma, St.
Louis, MO) for 2 days. GFP-positive cells were sorted
using a JSAN cell sorter (BayBioscience, Kobe, Japan).
Cell proliferation assay
In vitro cell proliferation was determined using an MTT
assay performed with a Cell Proliferation Kit I (Roche
Applied Science, Penzberg, Germany). Briefly, at 24 hr
after siRNA treatment, 2.5 × 103 cells per well were
seeded and incubated with MTT labeling reagent
(0.5 mg/ml) for 6 hr at 37°C. The soluble formazan
product was quantified using an ELISA reader at 590 nm
from day 1 to day 4.
Detection of dead cells
DNA damage-inducing agents were added when the
cells reached 80% confluence. CPT (Merck Millipore,
Billerica, MA) or ETP (Merck Millipore) was introduced
to the cells at a final concentration of 50 μM. After 24
to 72 hr, cells were harvested, washed with ice-cold PBS,
resuspended in PBS with 250 μg/ml RNase A, and
stained with 2× PI solution for 2 hr at 4°C. The cell cycle
was analyzed using FACSCalibur (BD, Franklin Lakes, NJ)
and CellQuest software.
Annexin XII/PI staining
Cells were washed twice with staining buffer (0.1 M Hepes
pH 7.4, 1.4 M NaCl, 25 mM CaCl2) and resuspended in
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on ice for 10 min. Cells were then counterstained with
0.5 μg/ml PI on ice for 5 min, and an equal volume of
staining buffer was added. Early apoptotic (Annexin XII
+/PI-) and late apoptotic/necrotic (Annexin XII+/PI+) cells
are shown with merged color.
EM analysis
After DSS1 knockdown, floating cells were centrifuged
in microfuge tubes and then fixed in 2.5% glutaraldehyde
in 0.1 M cacodylate buffer (pH 7.2) containing 0.1%
CaCl2. After washing in the same buffer, embedding in
2% agarose and incubating post-fixation in 1% OsO4 for
1 hr, the specimens were washed again, dehydrated in a
series of ethanol baths, and embedded in Epon 812. Thin
sections were cut with a Leica Ultracut UCT microtome,
post-stained with 2% uranyl acetate and Reynolds lead
citrate, and examined using a JEOL JEM 1400 operated
at 80 kV. Two researchers (TS and ST) independently
analyzed cells with apoptotic changes using digitized EM
images.Figure 1 Survival of patients with primary breast cancers. Patient surv
cancer patients were followed for more than 120 months and classified int
determined using qRT-PCR of total RNAs from 289 primary invasive breast
(n = 248) and high (n = 41) groups are shown. Statistical significance was c
respectively. (B) The patient survival was compared using double markers w
DSS1high (n = 31), p53high/DSS1low (n = 85), and p53high/DSS1high (n = 10) gr
(left) and *P = 0.045 (right), respectively.Alkaline comet assay
DNA damage induced by DSBs and single-strand breaks
were analyzed using a comet assay kit (Trevigen, Inc.,
Gaithersburg, MD), according to the manufacturer’s
protocol. For quantification, the tail moment (an index
of DNA damage calculated as the product of the tail
length and the fraction of DNA in the comet tail) was
evaluated using CometScore version 1.5 software (Auto-
Comet.com). At least a hundred cells from each sample
were scored.
Statistical analysis
The nonparametric Wilcoxon (for uni-variable), Kruskal-
Wallis test (for multi-variables), and the χ2 test were
adopted for statistical analysis of the associations between
the DSS1 mRNA status and various clinicopathological
factors. RFS and BCSS curves were calculated according
to the Kaplan-Meier method and verified by the log-rank
test. All statistical significance was defined as P < 0.05.
JMP software version 8.0.2 for Windows (SAS institute
Japan, Tokyo, Japan) was used for all statistical analyses.ival was assessed using the Kaplan-Meier method. Clinical breast
o groups based on the expression of DSS1 mRNA, which was
cancer patients. (A) BCSS (left) and RFS (right) of the DSS1 low
alculated as log-rank: n.s.P = 0.25 (left) and *P = 0.011 (right),
ith p53 and DSS1 mRNAs as p53low/DSS1low (n = 120), p53low/
oups. Statistical significance was calculated as log-rank: n.s.P = 0.49
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Increased DSS1 expression in breast cancer cases with
poor prognosis
We examined the survival of breast cancer patients
using the Kaplan-Meier method. We analyzed the expres-
sion level of DSS1 mRNA by qRT-PCR from the tumor
samples obtained at surgery using primers for DSS1
mRNA (Additional file 1: Figure S1). The relative expres-
sion level was arbitrarily determined and used for classifi-
cation of breast cancer cases into DSS1-high (DSS1high)
and DSS1-low (DSS1low) groups. The DSS1high group
showed a significant shorter survival time (*P = 0.011) on
the RFS curve, while the difference in the breast cancer
specific survival (BCSS) curves was not significant (n.s.;
P = 0.25) (Figure 1A). DSS1 physically interacts with the
RPN3/S3 proteasomal subunit, which increases the
degradation of ubiquitinated p53 [20]. In a large cohort,
over-expression of p53 was significantly associated with
poor prognosis in premenopausal women treated with
tamoxifen after chemotherapy [21]. The p53 expression
was used for classification by arbitrarily determined condi-
tions (see Methods). We compared RFS among p53low/
DSS1low, p53high/DSS1low, p53low/DSS1high, and p53high/
DSS1high groups (Figure 1B). While the number of cases
was small, no change of the survival curve was observed
when p53 expression was low; however, the DSS1high
group showed a worse prognosis in comparison with the
DSS1low group in breast cancer cases with high p53Table 1 Comparison of DSS1 gene expression among various





Tumor < 20 125












Ki67 < 20 113
(%) ≥ 20 169
(*) and (**) denote P < 0.05 and P < 0.01, respectively.expression (*P = 0.045). Other parameters and markers
were compared in the DSS1high and DSS1low groups
(Table 1). No significant differences were observed in the
groups of pre- or post-menopausal women, positive or
negative nodal status, tumor size < 20 or ≥ 20 mm, nuclear
grade I to III, positive or negative vessel invasion score,
ERα status, and PgR status. However, DSS1 expression
showed a significant difference (*P = 0.0255) based on
HER2 status, which is presumably associated with effective
treatment using trastuzumab as the standard regimen for
HER2-positive breast cancer cases. Interestingly, DSS1 ex-
pression was markedly increased (55.6; median of DSS1
relative expression) in the group of breast cancer cases
with low Ki67 labeling indices (< 20%) compared with the
expression (36.0; median of DSS1 relative expression) in
the group with high Ki67 labeling indices (≥ 20%).
The data suggest that the high DSS1 expression may
not be directly associated with the proliferation of breast
cancer cells in humans.
Effect of increased DSS1 expression on resistance to
chemotherapy
For molecular analysis, we used two breast cancer cell
lines, MCF7 (ERα+PgR+ with wild type p53) and MDA-
MB-231 (ERα-PgR- with p53 mutation). The effect of
DSS1 over-expression on cell proliferation and cell cycle
progression was examined in breast cancer cells that
had been engineered to over-express DSS1 (MCF7DSS1 orgroups of breast cancer patients
ene expression median (25%, 75%) Mann–Whitney U-test (P)
48.7 (8.05, 143) 0.554
49.2 (8.09, 92.4)
41.2 (7.04, 94.2) 0.132
64.9 (13.2, 117)
44.3 (8.08, 108) 0.646
52.2 (8.41, 104)
51.7 (8.33, 114) 0.703
39.7 (8.24, 90.0)
57.5 (6.19, 91.3)
40.0 (5.47, 88.9) 0.308
47.1 (11.5, 107)
52.7 (5.71, 105) 0.962
49.0 (8.36, 102)
60.3 (6.14, 103) 0.487
47.1 (8.37, 106)
53.2 (10.6, 115) *0.0255
21.8 (3.78, 74.8)
55.6 (16.4, 132) **0.0096
36.0 (4.97, 82.0)
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file 2: Figure S2). Stable transfectants that expressed high
levels of DSS1 mRNA did not show any changes in cell
cycle or cell proliferation compared with the control (GFP
only) transfectants (Figure 2A). DSS1-over-expressing
cells showed no abnormalities in proliferation. Trastuzu-
mab is a first choice for treatment of HER2-positive breast
cancer in our cohort, but camptothecin (CPT) is often
chosen as a regular regimen for HER2-negative breast
cancer cases (Table 1). The susceptibility of DSS1-over-
expressing breast cancer cells to the DNA-damage indu-
cing agents CPT and etoposide (ETP) was examined.
DSS1 over-expression renders breast cancer cells moreFigure 2 Effect of DSS1 over-expression on proliferation of the breas
was introduced using an ecotropic retroviral vector with GFP plus IRES sequ
sorted and used for cell proliferation assay on day 4 to day 5 after transfec
proliferation rates in the MTT assay (left) and cell counting (right). (B) Drug
optimized dose of CPT (50 μM) for 2 to 3 days. Results of the cell cycle pro
independent experiments. The proportions of dead cells were measured b
Statistical significance was calculated using Student’s t-test, with *P < 0.05 as s
cells. n.s.: not significant.resistant to treatment with CPT, an inhibitor of type
1 topoisomerase (which cleaves one strand of double-
stranded DNA), compared with the GFP-control
MCF7 transfectants (Figure 2B), while no change was
detected in DSS1 over-expressing MDA-MB-231 transfec-
tants (Figure 2C). The effect of DSS1 over-expression was
masked in both MCF7 and MDA-MB-231 cells upon
exposure to ETP, an inhibitor of topoisomerase II (which
cleaves two strands of double-stranded DNA and induces
cell cycle arrest at G2/M) (Additional file 3: Figure S3A
and B). Therefore, DNA damage was examined using the
alkaline comet assay (Figure 3A and B). DSS1 over-
expression reduced CPT-induced DNA damage in MCF7t cancer cell lines MCF7 and MDA-MB-231. Human DSS1 cDNA
ence. (A) DSS1 + GFP vector and GFP alone vector transfectants were
tion. DSS1 + GFP and GFP alone transfectants showed similar
sensitivity was examined in the MCF7 transfectants using an
file (left) are shown in the graph, which represents more than three
y counting the sub-G1 fraction and compared in the graph (right).
ignificant. (C) Drug sensitivity was similarly compared in MDA-MB-231
Figure 3 Effect of DSS1 over-expression on sensitivity to DNA damage. Effect of DSS1 over-expression on drug-induced DNA injury was
measured using the alkaline comet assay after treatment of cells with CPT (50 μM) for 3 hr. DMSO was used as a solvent control. The DNA
content pattern observed under fluorescent microscopy is shown (left), and the DNA damage rate was measured as the tail moment in the
fluorescence image using CometScore software. DSS-over-expressing MCF7 (A) or MDA-MB-231 (B) cells were compared with GFP-expressing
controls. Data obtained by counting more than 100 cells are shown as a graph, which represents more than three independent experiments
(right). Statistical significance was calculated using Student’s t-test, with **P < 0.01 as significant. Scale bar indicates 100 μm.
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expression increases drug resistance in breast cancers.
Effect of DSS1 knockdown on the sensitivity of breast
cancer cells carrying wild-type p53 or insufficient p53 to
chemotherapeutics
Next, we examined cell growth in DSS1-depleted cells.
Two siRNAs directed against two independent DSS1
mRNA sequences elicited marked reductions in DSS1
mRNA levels (Additional file 4: Figure S4A) and protein
levels (Additional files 4: Figure S4B and 5); we therefore
used one of these sequences in the following experi-
ments. DSS1 knockdown (siDSS1) caused decreased cell
growth, as observed in an MTT assay (Figure 4A: left)
and in an assessment of cell number (right). At 3 and
5 days after siDSS1-treatment, the number of dead cells
in the sub-G1 population increased compared to siCtrl-
treated cells (Figure 4B). siDSS1-treated MCF7 cells expe-
rienced cell cycle arrest at M phase entry, with increases
in G2/M phase populations at day 5 (27.0% vs. 6.20%).
siDSS1 also markedly induced the number of sub-G1
(dead) cells in drug-resistant MDA-MB-231 (24.8%, com-
pared with 3.99% for siCtrl).Treatment of MCF7 cells with siDSS1 caused apop-
tosis, as detected by staining with Annexin XII and
propidium iodide (PI). Representative Annexin XII+PI-
(early apoptotic) and Annexin XII+PI+ (late apoptotic/
necrotic) cells are shown in Figure 5A. We further
examined cell morphology at day 5 after siDSS1 treat-
ment using electron microscopy (EM). siDSS1 treatment
induced cell death in MCF7 cells, along with typical
apoptotic changes including chromatin condensation,
enlarged nuclei and smaller nuclei compared to the
siCtrl-treated cells (Figure 5B; chromatin condensation
marked with arrowheads). siDSS1 treatment also caused
apoptotic cell death in MDA-MB-231, with condensed
chromatin and smaller nuclei relative to the control cells
(Figure 5B; marked with arrowheads); however, some of
these cells also showed atypical cell death morphologies,
with enlarged cell size accompanied by electron micro-
scopically void nuclei containing finely condensed
chromatin-like structures adjacent to the inner nuclear
membrane (Figure 5B; marked with asterisks). Because
MDA-MB-231 do not seem to arrest at M phase entry,
presumably due to p53 mutation, the atypical cell death
observed in siDSS1-treated MDA-MB-231 might represent
Figure 4 Effect of DSS1 knockdown in the breast cancer cell lines MCF7 and MDA-MB-231. DSS1 knockdown was carried out in MCF7 and
MDA-MB-231 cells by treatment with siDSS1. Two siDSS1 sequences targeting two separate regions of the sequence showed similar knockdown
efficiencies and similar effects on the proliferation of MCF7 and MDA-MB-231 cells (Figure S4). (A) The proliferation rates of siCtrl- and siDSS1-(a)-
treated cells were assessed by MTT assay (left) and cell counting (right). (B) Cell cycle profiles of the transfectants were examined on day 3 and
day 5 of culture (right; day 5 profile). The proportions of dead cells were measured by the counting sub-G1 fraction and are compared in the
graph (right). The experiments were carried out more than three times, and the results are shown as an average. Statistical significance was
assessed by Student’s t-test, with *P < 0.05 and **P < 0.01.
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while the cell morphologies were not identical, siDSS1-
treated MCF7 and MDA-MB-231 cells showed similar
extents of DNA damage in the alkaline comet assay
(Figure 5C).
To confirm the effect of DSS1 on breast cancer cells,
we investigated the effect of DSS1 knockdown on cell
cycle and cell death in breast cancer cells during early
stages of treatment with CPT or ETP. DSS1 knockdown
markedly increased the number of cells in the sub-G1
apoptotic population in both MCF7 and MDA-MB-231
cells treated with CPT as early as day 2 (Figure 6A).
Similarly, DSS1 knockdown increased the sub-G1 popu-
lation in both breast cancer cell lines treated with ETP
(Figure 6B). Because MDA-MB-231 cells, which are of
mesenchymal origin and have a triple-negative pheno-
type [22], are well known to be resistant to several
DNA-damaging agents, these data suggested that
DSS1 depletion can increase chemosensitivity in drug-
resistant breast cancer cells with either wild type or
mutant p53.Discussion
Here, we demonstrate for the first time that DSS1 over-
expression can be used as an early diagnostic marker for
poor prognosis in cases of breast cancer. Because DSS1
maintains BRCA2 expression by regulating its ubiquitin-
dependent degradation [23] and because the BRCA1:
BRCA2 imbalance promotes tumorigenesis by increasing
genomic instability [24], we predicted that increased
expression of DSS1 could suppress breast cancer de-
velopment. However, unexpected results have been ob-
served in breast cancer cases. BRCA2 over-expression,
rather than decreased expression, is associated with a
poor survival rate [13] and poorer histological findings
[11] in breast cancer cohorts. Our finding agrees with
previous observations in cervical cancers with high
DSS1 expression [25] and in breast cancers with high
BRCA2 expression [11,13,14]. In a cervical cancer cohort
[25], human papilloma virus oncoprotein E6 was found
to bind to p53 and targets it for degradation through the
ubiquitin-proteasome system, which also regulates BRCA2
stabilization. The expression of DSS1 is upregulated in
Figure 5 Effect of DSS1 knockdown on apoptotic cell death in breast cancer cells. (A) To examine the stage of cell death, live cells were
stained with Annexin XII, which identifies the early apoptotic stage, in combination with PI staining; cells were marked as Annexin XII+PI-
(green; early apoptotic), Annexin XII+PI+ (doubly merged yellow; the intermediate stage), or Annexin XII-PI+ (red; late apoptotic/necrotic). Scale bar
indicates 100 μm. (B) EM analysis was carried out at day 5 after treatment with siCtrl or siDSS1-(a). Arrowheads show the chromatin condensation
typical of cell death, and asterisks indicate cell death with atypical chromatin accumulation and density. Scale bar indicates 500 μm. (C) An
alkaline comet assay was carried out to detect the DNA damage resulting from both single-strand and double-strand breaks and evaluated as in
Figure 3. Statistical significance was assessed by Student’s t-test, with **P < 0.01. Scale bar indicates 200 μm.
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http://www.biomedcentral.com/1471-2407/13/562cancerous regions compared to normal ones. The high
DSS1 expression that potentially maintains high-level
BRCA2 expression might cause or enhance breast cancer
proliferation and/or drug resistance.
Cells with insufficient levels of BRCA genes are unable
to repair DNA damage during the cell cycle and will
eventually die. Tumors with germline BRCA mutations
accompany the capacity to escape cell cycle checkpoints,
which is in accordance with the low incidence of mutant
BRCA-mediated sporadic tumorigenesis. BRCA2 inter-
acts with RAD51 and BRCA1 to mediate DNA repair,
P/CAF to mediate histone acetylation, BRAF-35 to
mediate cell cycle regulation, and DSS1 [26]. DNA
double-stranded breaks (DSBs) cause severe DNA dam-
age, leading to replication arrest. BRCA1 and BRCA2 are
involved in the repair of DSBs through their interaction
with RAD51. BRCA2 is primarily involved in HR repair,
but BRCA1 is involved in alternative DNA repair by non-
homologous end joining (NHEJ) [27]. These DNA repair
pathways are important for maintaining the integrity of the
genome against the DSBs that occur at various phases of
the cell cycle [28]. HR is principally involved in an error-
free DNA repair mechanism that protects the genomeduring the S phase of cell cycle when the allelic genes on
chromosomes are in close proximity [29]. Transcription-
coupled DNA damage occurring at the other phases of the
cell cycle is repaired by the NHEJ, which is required for
prompt DNA repair in rapidly proliferating cells regardless
of small errors in the genome [30]. The cellular genome is
presumably maintained by the balanced regulation of these
two DNA repair mechanisms [31].
The human DSS1 is homologous to Sem1, a component
of the Saccharomyces TREX2 complex, which is composed
of Sac3/Thp1/Sem1 in Saccharomyces cerevisiae. Thus, it
is likely to be a functional component of the GANP/
PCID2/ENY2/centrin/DSS1 complex involved in mRNA
export in mammalian cells [32]. Many studies have ad-
dressed the character and function of the individual com-
ponents of TREX2 complex in mammals [33]. Loss of any
component of the mammalian TREX2 complex elicited a
defect either in mRNA export or in the regulation of cell
cycle progression, implying that each TREX2 component
has an important individual function. Most of the defects
associated with loss of the TREX2 component involve
either replication or survival. In particular, DSS1 plays a
role in stabilization of BRCA2 through regulation of its
Figure 6 Effect of DSS1 knockdown on the drug sensitivity of MCF7 and MDA-MB-231 cells. Drug sensitivity was examined in DSS1
knockdown cells with an optimized dose of CPT (50 μM) and ETP (50 μM). MCF7 and MDA-MB-231 cells were first treated with siDSS1 for 2 days
and then cultured with CPT (A) or ETP (B) for 2 days. (A) and (B) The number of cells in the sub-G1 (dead) cell populations was compared
between siDSS1-(a)- or siCtrl-treated cells. The results of cell cycle profiling (left) were converted into the graph, which represents more than
three independent experiments (right). Statistical significance was assessed by Student’s t-test, with **P < 0.01 and ***P < 0.001.
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http://www.biomedcentral.com/1471-2407/13/562ubiquitin-dependent proteolytic degradation [23]. This may
suggest a unique function for DSS1 in the organization of
the ribonucleoprotein complex during various pro-
cesses: transcription, nuclear to cytoplasmic export,
and translation.
The p53high/DSS1high group showed a worse prognosis
in comparison with the p53low/DSS1high group in breast
cancer cases (Figure 1B), suggesting that the increased
p53 status accelerates the effect of DSS1 over-expression
on tumor progression under regular clinical treatments.
This effect was not simply represented in the CPT-
treatment of tumor cells between p53-wild type MCF7DSS1
and p53-mutated MDA-MB-231DSS1 (Figure 2C), while
both of which sustained similar DNA damages by CPT
under DSS1 over-expression (Figure 3). siDSS1, however,
rendered both tumor cells very sensitive to CPT and ETP
(Figure 6), suggesting that the effect of siDSS1 appears
dominantly on chemosensitivity of breast cancer cells
irrespective with TP53 status in the short-term culture.
DSS1 might be involved not only in the proteolytic
degradation of p53 [20], the stabilization of BRCA2 [23]and the process of DNA repair but also in the cell survival
against anti-cancer drugs.
Regarding the cause of the poor prognosis in high
DSS1-expressing breast cancers, an intriguing observation
is the marked enhancement of drug sensitivity in highly
drug-resistant MDA-MB-231 breast cancer cells by DSS1
knockdown (Figure 4). Drug resistance is caused by vari-
ous biological mechanisms in cancer cells, including phar-
macokinetic resistance and/or cellular resistance. Beside
the cellular drug transporter systems that allow multi-
drug resistance of breast cancer cells, decreases in various
nuclear enzymes could also cause multi-drug resistance.
Decreased activity of topoisomerases has been described
in several drug-resistant cancer cells including breast
cancers [34]. Defects in cellular signaling pathways leading
to apoptosis and DNA repair could result in multi-drug
resistance, as can p53 insufficiency, decreases in ceramide
levels [35], DNA alkyl-transferase activation [36], and
problems with the mismatch DNA repair system [37,38].
Decreased expression of BRCA2 has been suggested to be
a marker for a favorable response to docetaxel in breast
Rezano et al. BMC Cancer 2013, 13:562 Page 11 of 12
http://www.biomedcentral.com/1471-2407/13/562cancer [39]. BRCA2 knockdown has been proposed to as a
means to synergistically potentiate cisplatin and melphalan
treatment [40]. High DSS1 expression, which potentially
stabilizes BRCA2 and maintains cancer cell proliferation,
could increase drug resistance under the standard clinical
regimens of breast cancer treatment, presumably resulting
in decreased disease-free survival.
Conclusions
Sporadic cases of breast cancer with high expression of
DSS1 showed a worse prognosis with respect to RFS;
however, increased DSS1 expression was not correlated
with increased proliferation or tumor grade. DSS1 over-ex-
pression increased the resistance of breast cancer cells to
DNA-damaging drugs; conversely, DSS1 knockdown ren-
dered breast cancer cells more sensitive to these drugs.
These results clearly indicate that DSS1 knockdown in
combination with chemotherapy might be effective for
treatment of breast cancer.
Additional files
Additional file 1: Figure S1. Differences between the DSS1high and the
DSS1low groups based on qRT-PCR. Patients having tumors with high
DSS1 expression were classified by the mRNA level as the DSS1high group
(DSS1/β-actin ratio > 136). Boxes represent the mean and 70% confidence
intervals; bars, standard deviations.
Additional file 2: Figure S2. Establishment of DSS1 over-expressed
MCF7 and MDA-MB-231 cells. (A) Schematic diagram of retroviral vectors
(pFB-IRES-GFP and pFB-DSS1-IRES-GFP). (B) Increased expression of DSS1
transcripts in DSS1 over-expressed MCF7 and MDA-MB-231 cells.
Representative data is shown from three independent experiments.
Additional file 3: Figure S3. Drug sensitivity in DSS1 over-expressed
MCF7 and MDA-MB-231 cells. (A) and (B) The effect of DSS1 over-
expression on drug sensitivity was examined in MCF7 and MDA-MB-231
cells at day 2 and day 3 after treatment with ETP (50 μM). n.s.: not
significant.
Additional file 4: Figure S4. Effect of siDSS1 on DSS1 expression and
cell proliferation. (A) siDSS1s on two independent sequences were
transfected into MCF7 and MDA-MB-231 cells. The expression levels of
DSS1 transcripts were measured by qRT-PCR. Similar knockdown
efficiency was observed in both siDSS1-(a) and siDSS1-(b) transfected cells.
The data are representative of three independent experiments. (B) The
expression levels of DSS1 were measured by Western blot in siCtrl-,
siDSS1-(a)-, and siDSS1-(b)-treated cells. β-actin was used as a loading
control. (C) Effect of siDSS1-(b) was similar in cell proliferation
(MTT assay) compared with that of siDSS1-(a) shown in Figure 4. Statistical
significance is shown by the Student’s t-test calculation with **P < 0.01
and ***P < 0.001.
Additional file 5: Western blot analysis.
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